Medical and Other Studies

What Studies Say about Hemp CBD

CBD is a phytocannabinoid that is found in industrial hemp and marijuana, which are two different varieties of the Cannabis sativa plant.

The current market for CBD as a dietary supplement is based on industrial hemp, not marijuana, because marijuana also contains significant amounts of tetrahydrocannabinol (THC), a phytocannabinoid that is psychoactive and, thus, capable of making a person high. Industrial hemp contains only negligible amounts of THC-no more than, say, poppy seeds contain opiates—and so it will not get you high. The plant is, thus, safe for human consumption and useful for components including CBD.
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

Multiple sclerosis subjects with a clinical diagnosis of central neuropathic pain entered a seven to ten day baseline period, followed by a four week double blind, randomised, parallel group comparison of Sativex, with placebo. The study medication was self-titrated to symptom resolution or maximum tolerated or allowed dose. Visits occurred at the end of weeks one and four (end of the study) or earlier if they withdrew. A follow-up visit occurred 30 - 40 days after completion or withdrawal.
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Eligible patients entered this 50 week multicenter, double-blind, randomised, placebo-controlled, parallel group study which evaluated the effect of Sativex on cognitive performance. At each scheduled clinic visit, patients were assessed for cognitive performance, mood, severity of spasticity, use of investigational medicinal products and number of visits to a healthcare professional. Primary efficacy comparisons were made between scores recorded during baseline and scores recorded at the end of treatment.

nhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol

CBD BDS attenuates colon carcinogenesis​ and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.
Chronic administration of cannabidiol to healthy volunteers and epileptic patients

4 of the 8 CBD subjects remained almost free of convulsive crises and 3 other patients demonstrated partial improvement.
Treatment of Meige’s syndrome with cannabidiol

50% improvement in spasm severity and frequency.
Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia

Improvement of dyskinesia.
Cannabidiol in dystonic movement disorders

Cannabidiol (CBD) reduced dystonic movements.
Open label evaluation of cannabidiol in dystonic movement disorders

20-50% improvement of dystonia; deterioration of tremor and hypokinesia in 2 patients with Parkinson's disease.
Controlled clincal trial of cannabidiol in Huntington’s diseas e

CBD was neither symptomatically effective nor toxic.
Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1

Data demonstrate cannabinoid-induced upregulation of ICAM-1 on lung cancer cells to be responsible for increased cancer cell lysis by LAK cells. These findings provide proof for a novel antitumorigenic mechanism of cannabinoids.
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

Pain relief associated with both THC and CBD was significantly superior to placebo. Impaired bladder control, muscle spasms and spasticity were improved by cannabis in some patients.
Effect of THC and CBD on nocturnal sleep and early-morning behavior in young adults

THC had sedative effects, CBD had alerting effects.
Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study

Significant reduction of intraocular pressure
Cannabidiol monotherapy for treatment-resistant schizophrenia

CBD monotherapy was not effective in treatment-resistant schizophrenia.
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder

CBD reduces anxiety in patients with generalized social anxiety disorder
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Cannabidiol significamtly reduced anxiety.
S ubjective and Physiological Effects After Controlled Sativex and Oral THC Administration

Oral THC and the cannabis extract Sativex produced similar effects.
Acute effects of a single, oral dose of THC and CBD administration in healthy volunteers

CBD does not cause significant side effects
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

CBD was as effective as amisulpride, a standard antipsychotic.
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report

There were no major withdrawal symptoms.
Cannabidiol enhances consolidation of explicit fear extinction in humans

Cannabidiol enhances consolidation of fear extinction in humans.